Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Apple

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Drugs in R&D|June 20, 2022
Analysis of the US Safety Data for Edaravone (Radicava<sup>®</sup>) From the Third Year After LaunchAngela Genge, Benjamin Rix Brooks, Björn Oskarsson, et al.
The Review of Scientific Instruments|July 3, 2017
A new torsion pendulum for gravitational reference sensor technology developmentGiacomo Ciani, Andrew Chilton, Stephen Apple, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 28, 2020
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19Ammar Al-Chalabi, Adriano Chiò, Charlotte Merrill, et al.
Neuroepidemiology|June 21, 2021
Current and Future Projections of Amyotrophic Lateral Sclerosis in the United States Using Administrative Claims DataChris Miller, Stephen Apple, Jeremy S Paige, et al.
Muscle & Nerve|November 24, 2021
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19Benjamin Rix Brooks, Erik P Pioro, Jonathan Katz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 16, 2019
<i>Post-hoc</i> analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosisJoseph M Palumbo, Jean Hubble, Stephen Apple, et al.
Muscle & Nerve|July 1, 2025
Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo ControlsFumihiro Takahashi, Angela Genge, Manabu Hirai, et al.
Muscle & Nerve|October 18, 2019
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)Jeremy Shefner, Terry Heiman-Patterson, Erik P Pioro, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Drugs in R&D|June 20, 2022
Analysis of the US Safety Data for Edaravone (Radicava<sup>®</sup>) From the Third Year After LaunchAngela Genge, Benjamin Rix Brooks, Björn Oskarsson, et al.
The Review of Scientific Instruments|July 3, 2017
A new torsion pendulum for gravitational reference sensor technology developmentGiacomo Ciani, Andrew Chilton, Stephen Apple, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 28, 2020
Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19Ammar Al-Chalabi, Adriano Chiò, Charlotte Merrill, et al.
Neuroepidemiology|June 21, 2021
Current and Future Projections of Amyotrophic Lateral Sclerosis in the United States Using Administrative Claims DataChris Miller, Stephen Apple, Jeremy S Paige, et al.
Muscle & Nerve|November 24, 2021
Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19Benjamin Rix Brooks, Erik P Pioro, Jonathan Katz, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|April 16, 2019
<i>Post-hoc</i> analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosisJoseph M Palumbo, Jean Hubble, Stephen Apple, et al.
Muscle & Nerve|July 1, 2025
Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo ControlsFumihiro Takahashi, Angela Genge, Manabu Hirai, et al.
Muscle & Nerve|October 18, 2019
Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19)Jeremy Shefner, Terry Heiman-Patterson, Erik P Pioro, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 12, 2021
Evidence for generalizability of edaravone efficacy using a novel machine learning risk-based subgroup analysis toolBenjamin Rix Brooks, Erik P Pioro, Danielle Beaulieu, et al.
Neurology. Clinical Practice|September 3, 2021
Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study DesignJames Berry, Benjamin Brooks, Angela Genge, et al.
Pageof 3